These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22404285)

  • 21. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e305-7. PubMed ID: 15173053
    [No Abstract]   [Full Text] [Related]  

  • 22. Reporting of sample-size calculations for randomized trials in dermatology: comparison of publications with registries.
    Weinberg T; Wang G; Lam K; Kitchen J; Chan AW
    Br J Dermatol; 2019 Apr; 180(4):929-930. PubMed ID: 30339744
    [No Abstract]   [Full Text] [Related]  

  • 23. Statistical principles: myths or facts?
    Sylvester R
    Onkologie; 2003 Dec; 26(6):520-1. PubMed ID: 14709923
    [No Abstract]   [Full Text] [Related]  

  • 24. Statistical trial designs and clinical practice: are they compatible?
    Punt CJ
    Onkologie; 2003 Dec; 26(6):518-9. PubMed ID: 14709922
    [No Abstract]   [Full Text] [Related]  

  • 25. Editorial: Randomised controlled trials of factorial design alias on how to speed up research on effectiveness of interventions without compromising its validity.
    Esposito M; Nieri M
    Eur J Oral Implantol; 2016; 9(1):3-4. PubMed ID: 27022633
    [No Abstract]   [Full Text] [Related]  

  • 26. Statistics Commentary Series. Commentary No. 43: Patient Preference Trials.
    Streiner DL
    J Clin Psychopharmacol; 2020; 40(6):529-530. PubMed ID: 33044357
    [No Abstract]   [Full Text] [Related]  

  • 27. Review of randomized controlled trials: issues to consider when designing a trial.
    Pandis N
    Am J Orthod Dentofacial Orthop; 2013 Jun; 143(6):905-7. PubMed ID: 23726342
    [No Abstract]   [Full Text] [Related]  

  • 28. Randomized controlled trials.
    Jainer AK; Chawla M
    Am J Psychiatry; 2003 Jun; 160(6):1189-90; author reply 1190. PubMed ID: 12777289
    [No Abstract]   [Full Text] [Related]  

  • 29. Subgroup analyses.
    Oxman AD
    BMJ; 2012 Mar; 344():e2022. PubMed ID: 22422834
    [No Abstract]   [Full Text] [Related]  

  • 30. Introducing the new CONSORT extension for stepped-wedge cluster randomised trials.
    Hemming K; Taljaard M; Grimshaw J
    Trials; 2019 Jan; 20(1):68. PubMed ID: 30658677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reported methodological quality of split-mouth studies.
    Lesaffre E; Garcia Zattera MJ; Redmond C; Huber H; Needleman I;
    J Clin Periodontol; 2007 Sep; 34(9):756-61. PubMed ID: 17716311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statistics Commentary Series. Commentary No. 44: Internal and External Validity.
    Streiner DL
    J Clin Psychopharmacol; 2020; 40(6):531-533. PubMed ID: 33044353
    [No Abstract]   [Full Text] [Related]  

  • 33. Sympathetic bias.
    Levy DM; Peart SJ
    Stat Methods Med Res; 2008 Jun; 17(3):265-77. PubMed ID: 17925315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse events in randomized trials: neglected, restricted, distorted, and silenced.
    Ioannidis JP
    Arch Intern Med; 2009 Oct; 169(19):1737-9. PubMed ID: 19858427
    [No Abstract]   [Full Text] [Related]  

  • 35. Sample size calculations for randomized controlled trials.
    Wittes J
    Epidemiol Rev; 2002; 24(1):39-53. PubMed ID: 12119854
    [No Abstract]   [Full Text] [Related]  

  • 36. The fragility index can be used for sample size calculations in clinical trials.
    Baer BR; Gaudino M; Fremes SE; Charlson M; Wells MT
    J Clin Epidemiol; 2021 Nov; 139():199-209. PubMed ID: 34403756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Electronic monitoring: who needs a trojan horse?
    Vintzileos AM
    Birth; 1994 Dec; 21(4):235-6. PubMed ID: 7857472
    [No Abstract]   [Full Text] [Related]  

  • 38. [STRENGTHS AND WEAKNESSES OF RANDOMISED CLINICAL TRIALS: EVOLVING CHANGES ACCORDING TO PERSONALIZED MEDICINE].
    Ernest P; Jandrain B; Scheen AJ
    Rev Med Liege; 2015; 70(5-6):232-6. PubMed ID: 26285444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized trials for the real world: making as few and as reasonable assumptions as possible.
    Baker SG; Kramer BS
    Stat Methods Med Res; 2008 Jun; 17(3):243-52. PubMed ID: 17925312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Re: The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials.
    Shrier I
    Stat Med; 2008 Jun; 27(14):2740-1; author reply 2741-2. PubMed ID: 18069729
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.